Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accounts Payables: 2018-2024

Historic Accounts Payables for Bicycle Therapeutics (BCYC) over the last 7 years, with Dec 2024 value amounting to $15.8 million.

  • Bicycle Therapeutics' Accounts Payables rose 121.44% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 121.44%. This contributed to the annual value of $15.8 million for FY2024, which is 21.02% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Accounts Payables stood at $15.8 million for FY2024, which was up 21.02% from $13.1 million recorded in FY2023.
  • In the past 5 years, Bicycle Therapeutics' Accounts Payables registered a high of $15.8 million during FY2024, and its lowest value of $1.4 million during FY2020.
  • Its 3-year average for Accounts Payables is $11.8 million, with a median of $13.1 million in 2023.
  • Its Accounts Payables has fluctuated over the past 5 years, first declined by 29.96% in 2020, then spiked by 137.85% in 2022.
  • Bicycle Therapeutics' Accounts Payables (Yearly) stood at $1.4 million in 2020, then surged by 99.34% to $2.7 million in 2021, then surged by 137.85% to $6.5 million in 2022, then skyrocketed by 101.64% to $13.1 million in 2023, then increased by 21.02% to $15.8 million in 2024.